Current concepts in the evaluation and management of WHO grade II gliomas

Journal of Neuro-Oncology

Volumn 92, Issue 3 SPEC. ISS., 2009, Pages 253-259

  Piepmeier, Joseph M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Low grade glioma; Radiation therapy; Surgery

Indexed keywords

METHIONINE C 11; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ASTROCYTOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CHROMOSOME 19Q; CHROMOSOME 1P; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; DRUG HALF LIFE; GENE DELETION; GENETIC ASSOCIATION; GLIOMA; HUMAN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR VOLUME; WORLD HEALTH ORGANIZATION;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOMA; HUMANS; WORLD HEALTH ORGANIZATION;

EID: 65249118318     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9870-z     Document Type: Review

References (34)

1. Piepmeier J, Christopher S, Spencer D, Byrne T, Kim J, Knisely J, Lacy J, Tsukerman L, Makuch R (1996) Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery 38:872-879. doi: 10.1097/00006123-199605000-00002
2. Piepmeier J (1987) Observations on the current treatment of low grade astrocytic tumors of the cerebral hemispheres. J Neurosurg 67:177-181
3. Rees J, Watt H, Jäger HR, Benton C, Tozer D, Tofts P, Waldman A (2008) Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation. Eur J Radiol [Epub ahead of print]
4. Chang E, Smith J, Chang S, Lamborn S, Prados M, Butowski N, Barbaro N, Parse A, Berger M, McDermott M (2008) Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg 109:817-824. doi: 10.3171/JNS/2008/109/11/0817
5. Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, Wara W, MacDonald D, Stitt L, Cairncross JG (1999) Pretreatment factors predict overall survival for patients with low-grade glioma: A recursive partitioning analysis. Int J Radiat Oncol Biol Phys 45(4):923-929. doi: 10.1016/S0360-3016(99)00284-9
6. Trembath D, Miller CR, Perry A (2008) Gray zones in brain tumor classification: Evolving concepts. Adv Anat Pathol 15(5):287-297. doi: 10.1097/PAP.0b013e3181836a03
7. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26(8):1338-1345. doi: 10.1200/JCO.2007.13.9337
8. Claus EB, Horlacher A, Hsu L, Schwartz RB, Dello-Iacono D, Talos F, Jolesz FA, Black PM (2005) Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer 103(6):1227-1233. doi: 10.1002/cncr.20867
9. Robles SG, Gatignol P, Lehéricy S, Duffau H (2008) Long-term brain plasticity allowing a multistage surgical approach to World Health Organization Grade II gliomas in eloquent areas. J Neurosurg 109(4):615-624. doi: 10.3171/JNS/2008/109/10/0615
10. Sanai N, Berger MS (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery 62(4):753-764. doi: 10.1227/ 01.neu.0000318159.21731.cf
11. Shaw EG, Berkey B, Coons SW, Bullard D, Brachman D, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta M (2008) Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: Results of a prospective clinical trial. J Neurosurg 109(5):835-841. doi: 10.3171/JNS/2008/109/11/0835
12. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmström PO, Collette L, Piérart M, Mirimanoff R, Karim AB (2005) EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomised trial. Lancet 366(9490):985-990. doi: 10.1016/ S0140-6736(05)67070-5
13. Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, Mascarenhas F, Horiot JC, Parvinen LM, van Reijn M, Jager JJ, Fabrini MG, van Alphen AM, Hamers HP, Gaspar L, Noordman E, Pierart M, van Glabbeke M (1996) A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 36(3):549-556. doi: 10.1016/S0360-3016(96)00352-5
14. Shaw EG, Tatter SB, Lesser GJ, Ellis TL, Stanton CA, Stieber VW (2004) Current controversies in the radiotherapeutic management of adult low-grade glioma. Semin Oncol 31(5):653-658. doi: 10.1053/ j.seminoncol.2004.07.007
15. Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard MA, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon JM, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre JY, Hoang-Xuan K (2007) Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome. Neurology 68(21):1831-1836. doi: 10.1212/01.wnl.0000262034.26310.a2
16. Sijens PE, Heesters MA, Enting RH, van der Graaf WT, Potze JH, Irwan R, Meiners LC, Oudkerk M (2007) Diffusion tensor imaging and chemical shift imaging assessment of heterogeneity in low grade glioma under temozolomide chemotherapy. Cancer Invest 25(8):706-710. doi: 10.1080/ 07357900701564028
17. Idbaih A, Carvalho Silva R, Crinière E, Marie Y, Carpentier C, Boisselier B, Taillibert S, Rousseau A, Mokhtari K, Ducray F, Thillet J, Sanson M, Hoang-Xuan K, Delattre JY (2008) Genomic changes in progression of low-grade gliomas. J Neurooncol [Epub ahead of print]
18. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66(20):9852-9861. doi: 10.1158/0008-5472.CAN-06-1796
19. Ngo TT, Peng T, Liang XJ et al (2007) The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst 99:639-652. doi: 10.1093/jnci/djk135
20. Liang XJ, Choi Y, Sackett DL, Park JK (2008) Nitrosoureas inhibit the stathmin-mediated migration and invasion of malignant glioma cells. Cancer Res 68(13):5267-5272. doi: 10.1158/0008-5472.CAN-07-6482
21. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26(25):4189-4199. doi: 10.1200/JCO.2007.11.5964
22. Möllemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113(3):379-385. doi: 10.1002/ijc.20575
23. Lavon I, Zrihan D, Zelikovitch B, Fellig Y, Fuchs D, Soffer D, Siegal T (2007) Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Clin Cancer Res 13(5):1429-1437. doi: 10.1158/ 1078-0432.CCR-06-2050
24. Campbell B, Horsman D, Maguire J, Young S et al (2008) Chromosomal alterations in oligodendroglial tumours over multiple surgeries: Is tumour progression associated with change in 1p/19q status? J Neurooncol 89:37-45. doi: 10.1007/s11060-008-9597-2
25. Mainio A, Tuunanen S, Hakko H, Niemelä A, Koivukangas J, Räsänen P (2006) Decreased quality of life and depression as predictors for shorter survival among patients with low grade gliomas: A follow-up from 1990 to 2003. Eur Arch Psychiatry Clin Neurosci 256(8):516-521. doi: 10.1007/s00406-006-0674-2
26. Correa DD, Shi W, Thaler HT, Cheung AM, DeAngelis LM, Abrey LE (2008) Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol 86(3):321-327. doi: 10.1007/s11060-007-9474-4
27. Brown R, Zlatescu M, Sijben A, Roldan G, Easaw J, Forsyth P, Parney I, Sevick R, Yan E, Demetrick D, Schiff D, Cairncross G, Mitchell R (2008) The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res 14(8):2357-2362. doi: 10.1158/1078-0432.CCR-07-1964
28. Roelcke U, Wyss M, Bärtschi E, Hofer S (2007) Metabolic deactivation of low-grade glioma during chemotherapy. J Neurol 254(5):668-669. doi: 10.1007/s00415-006-0321-x
29. Tozer DJ, Jäger HR, Danchaivijitr N, Benton CE, Tofts PS, Rees JH, Waldman AD (2007) Apparent diffusion coefficient histograms may predict low-grade glioma subtype. NMR Biomed 20(1):49-57. doi: 10.1002/nbm.1091
30. Danchaivijitr N, Waldman AD, Tozer DJ, Benton CE, Brasil Caseiras G, Tofts PS, Rees JH, Jäger HR (2008) Low-grade gliomas: Do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology 247(1):170-178
31. Law M, Oh S, Johnson G, Babb JS, Zagzag D, Golfinos J, Kelly PJ (2006) Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: A second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery 58(6):1099-1107. doi: 10.1227/01.NEU.0000215944.81730.18
32. Baehring J, Bi L, Bannyhk S, Piepmeier J, Fulbright R (2007) Diffusion MRI in the early diagnosis of malignant glioma. J Neurooncol 82(2):221-225. doi: 10.1007/s11060-006-9273-3
33. Kato T, Shinoda J, Oka N, Miwa K, Nakayama N, Yano H, Maruyama T, Muragaki Y, Iwama T (2008) Analysis of 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity. AJNR Am J Neuroradiol [Epub ahead of print]
34. Gozé C, Rigau V, Gibert L, Maudelonde T, Duffau H (2009) Lack of complete 1p19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: A marker of worse prognosis? J Neurooncol 91(1):1-5. doi: 10.1007/s11060-008-9680-8